(Q39496812)

English

Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

0 references

0 references

0 references

Low-dose naltrexone

0 references

author name string

Renee N Donahue

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Patricia J McLaughlin

2

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Ian S Zagon

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

publication date

1 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Experimental Biology and Medicine

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

236

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1036-1050

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

On the specificity of naloxone as an opiate antagonist

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Evidence for a role of opioids in epoxyeicosatrienoic acid-induced cardioprotection in rat hearts.

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Naltrexone effects on male sexual behavior, corticosterone, and testosterone in stressed male rats

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Low-dose naltrexone therapy improves active Crohn's disease

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

A GPCR/secretase complex regulates beta- and gamma-secretase specificity for Abeta production and contributes to AD pathogenesis.

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: a role for endogenous opioid systems in cancer

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

The biology of the opioid growth factor receptor (OGFr)

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Increased brain size and cellular content in infant rats treated with an opiate antagonist

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Endogenous opioid systems regulate cell proliferation in the developing rat brain

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Gene-peptide relationships in the developing rat brain: the response of preproenkephalin mRNA and [Met5]-enkephalin to acute opioid antagonist (naltrexone) exposure

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Ontogeny of zeta (zeta), the opioid growth factor receptor, in the rat brain

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Modulation of human neuroblastoma transplanted into nude mice by endogenous opioid systems

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Naloxone modulates body and organ growth of rats: dependency on the duration of opioid receptor blockade and stereospecificity

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Chronic naloxone results in prolonged increases in opiate binding sites in brain

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Naltrexone reduces weight gain, alters "beta-endorphin", and reduces insulin output from pancreatic islets of genetically obese mice

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Supersensitivity to opioids following the chronic blockade of endorphin action by naloxone

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Enhanced analgesic effects of morphine after chronic administration of naloxone in the rat

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Human renal cell cancer proliferation in tissue culture is tonically inhibited by opioid growth factor

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Defects in the opioid growth factor receptor in human squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

The expression and function of the OGF-OGFr axis - a tonically active negative regulator of growth - in COS cells

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Stereospecific modulation of tumorigenicity by opioid antagonists

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Endogenous opioid systems regulate growth of neural tumor cells in culture

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Production and characterization of polyclonal and monoclonal antibodies to the zeta (zeta) opioid receptor

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Opioid antagonist (naltrexone) stimulation of cell proliferation in human and animal neuroblastoma and human fibrosarcoma cells in culture

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Treatment of advanced pancreatic cancer with opioid growth factor: phase I.

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.011121

21 January 2018

Identifiers

10.1258/EBM.2011.011121

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39496812&oldid=1832098172"